Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery.

Hall FL, Levy JP, Reed RA, Petchpud WN, Chua VS, Chawla SP, Gordon EM.

Oncol Rep. 2010 Oct;24(4):829-33.

PMID:
20811660
3.

Rexin-G, a targeted genetic medicine for cancer.

Gordon EM, Hall FL.

Expert Opin Biol Ther. 2010 May;10(5):819-32. doi: 10.1517/14712598.2010.481666. Review.

PMID:
20384524
4.

The 'timely' development of Rexin-G: first targeted injectable gene vector (review).

Gordon EM, Hall FL.

Int J Oncol. 2009 Aug;35(2):229-38. Review.

PMID:
19578735
5.

Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.

Gordon EM, Levy JP, Reed RA, Petchpud WN, Liu L, Wendler CB, Hall FL.

Int J Oncol. 2008 Oct;33(4):665-75.

PMID:
18813779
6.

Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience.

Gordon EM, Lopez FF, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Bruckner HW, Hall FL.

Int J Oncol. 2006 Nov;29(5):1053-64.

PMID:
17016635
7.

First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.

Gordon EM, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Hall FL.

Int J Oncol. 2004 Jan;24(1):177-85.

PMID:
14654955

Supplemental Content

Loading ...
Support Center